Skip to content

Efficacy of repetitive transcranial magnetic stimulation in drug-resistant Obsessive Compulsive Disorder.

Efficacy of adjunctive rTMS in pharmacoresistant OCD: A Randomized, sham controlled study. - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/077787
Enrollment
34
Registered
2024-12-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F42- Obsessive-compulsive disorder

Interventions

Intervention1: Adjunctive low frequency rTMS: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique proposed as a promising method for treating OCD via alt

Sponsors

Dr Vishakha Srivastava
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Resistant OCD patients i.e., patients showing less than 35% improvement in YBOCS score greater than 16 after receiving 6-8 weeks treatment of combination of at least 2 first line drugs in OCD including SSRIs’, CLOMIPRAMINE, in maximum tolerable recommended dosages. 2.Patient aged between 18 and 60 years 3.Patient from both gender 4.Patient/Patient’s caregivers who will give written consent for the study 5.All patients will stable on medication for about 6 weeks prior to participating in study.

Exclusion criteria

Exclusion criteria: 1.Those who do not give consent. 2.Who has history of seizures.

Design outcomes

Primary

MeasureTime frame
To determine the efficacy of low frequency rTMS (1 Hz, 110 % MT, 1200 pulses/day) over supplementary motor as an augmentation treatment in cases of pharmacoresistant OCD patients.Timepoint: 6 months

Secondary

MeasureTime frame
to see the adverse effects of rTMS To see the changes in BDI score and QoLTimepoint: 2weeks, 4weeks

Countries

India

Contacts

Public ContactDr Mohammad Reyazuddin

Jawaharlal Nehru Medical College AMU

reyaz39@gmail.com9997258800

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026